A congenital heart defect (CHD), also known as a congenital heart anomaly or congenital heart disease, is a problem in the structure of the heart that is present at birth. Signs and symptoms depend on the specific type of problem. Symptoms can vary from none to life-threatening. When present they may include rapid breathing, bluish skin, poor weight gain, and feeling tired. It does not cause chest pain. Most congenital heart problems do not occur with other diseases. Complications that can result from heart defects include heart failure.
This report contains market size and forecasts of Congenital Heart Disease Treatment in Global, including the following market information:
Global Congenital Heart Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Congenital Heart Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Medication Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Congenital Heart Disease Treatment include Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic and BD, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Heart Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Congenital Heart Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Congenital Heart Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Medication
Surgical Therapy
Global Congenital Heart Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Congenital Heart Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals and Clinics
Diagnostic Centers
Global Congenital Heart Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Congenital Heart Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Congenital Heart Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Congenital Heart Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Abbott Laboratories
Roche
GSK
Sanofi
Johnson & Johnson
Medtronic
BD
Boston Scientific
Merck
Eli Lilly
Mylan
Sun Pharmaceutical
AstraZeneca